Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China’s Hua Medicine Licenses Worldwide Rights To Roche Diabetes Compound, More Deals On The Way

This article was originally published in PharmAsia News

Executive Summary

Chinese startup Hua Medicine kicks off its in-licensing strategy with an IND-ready glucokinase activator from Roche.

You may also be interested in...



Ascletis Opens Its $100 Million Wallet - Breaks Ground On China Facility, Sets Sights On In-Licensing

HANGZHOU, China - U.S.-China hybrid Ascletis Inc. is putting some of its $100 million Series A funding to immediate use, breaking ground Oct. 20 on a facility in Zhenjiang Province that will house its China headquarters and R&D center

As Management Talent Moves To China Startups, Will Industry See More In-Licensing Deals?

SHANGHAI - Beijing-based biotech startup BeiGene Ltd. announced its first in-licensing deal this month for two clinical-stage oncology compounds from Janssen Pharmaceutical NV, a division of Johnson & Johnson.

Meet China’s New Innovators: Hua Medicine Looks To Take Flight With U.S. Venture Backing (Part 1)

When multinational pharmaceutical companies began to establish R&D facilities in China a decade ago, they counted on Chinese returnees, or "sea turtles," to head the new centers and help them get the lay of the land. Now, MNCs may soon be partnering - or competing - with these same sea turtles who have switched gears to become China's newest entrepreneurs

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC076988

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel